Novel options for the treatment of castration-resistant prostate cancer

被引：12

作者：

Ohlmann, Carsten-H. ^{[1
]}

Merseburger, Axel S. ^{[2
]}

Suttmann, Henrik ^{[3
]}

Schilling, David ^{[4
]}

Trojan, Lutz ^{[5
]}

Kempkensteffen, Carsten ^{[6
]}

Corvin, Stefan ^{[7
]}

Mathers, Michael J. ^{[8
]}

Bastian, Patrick J. ^{[9
]}

机构：

[1] Univ Saarland, Dept Urol, D-66421 Homburg, Germany

[2] Hannover Med Sch, Dept Urol, D-3000 Hannover, Germany

[3] Urologikum Hamburg, Hamburg, Germany

[4] Univ Tubingen, Dept Urol, Tubingen, Germany

[5] Heidelberg Univ, Dept Urol, Med Fac Mannheim, D-6800 Mannheim, Germany

[6] Univ Med Berlin, Dept Urol, Charite, Berlin, Germany

[7] Fachzentrum Urol Eggenfelden, Eggenfelden, Germany

[8] PandaMED Remscheid, Remscheid, Germany

[9] Univ Munich, Urol Klin & Poliklin, Klinikum Univ Campus Grosshadern, Munich, Germany

来源：

WORLD JOURNAL OF UROLOGY | 2012年 / 30卷 / 04期

关键词：

Castration-resistant prostate cancer; Abiraterone; MDV3100; Zibotentan; Denosumab; Alpharadin; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED PHASE-II; EVERY; 3; WEEKS; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; SIPULEUCEL-T; TUMOR PROGRESSION; CONTROLLED-TRIAL; CLINICAL-TRIAL; DOCETAXEL;

D O I：

10.1007/s00345-011-0796-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

引用

下载

页码：495 / 503

页数：9

共 50 条

[21] Sequencing Treatment for Castration-Resistant Prostate Cancer
Handy, Catherine E.
Antonarakis, Emmanuel S.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
[22] Sequencing Treatment for Castration-Resistant Prostate Cancer
Catherine E. Handy
Emmanuel S. Antonarakis
Current Treatment Options in Oncology, 2016, 17
[23] Current therapeutic options in metastatic castration-resistant prostate cancer
Ingrosso, Gianluca
Detti, Beatrice
Scartoni, Daniele
Lancia, Andrea
Giacomelli, Irene
Baki, Muhammed
Carta, Giulio
Livi, Lorenzo
Santoni, Riccardo
SEMINARS IN ONCOLOGY, 2018, 45 (5-6) : 303 - 315
[24] Identification of novel molecular targets for treatment of castration-resistant prostate cancer
Moselhy, Jim
Roy, Ram V.
Suman, Suman
Das, Trinath P.
Ankem, Murali
Damodaran, Chendil
CANCER RESEARCH, 2015, 75
[25] Synthesis of novel tanshinone derivatives for treatment of castration-resistant prostate cancer
Xu, Defeng
Hu, Hang
Guan, Jing
Da, Jun
Xie, Yipeng
Liu, Yalin
Kong, Ren
Song, Guoqiang
Zhou, Huan
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 94 (03) : 1656 - 1663
[26] Combined Androgen Blockade Revisited: Emerging Options for the Treatment of Castration-Resistant Prostate Cancer
Simmons, Matthew N.
Klein, Eric A.
UROLOGY, 2009, 73 (04) : 697 - 705
[27] Metastatic castration-resistant prostate cancer-what are rational sequential treatment options?
Horak, Jana
Petrausch, Ulf
Omlin, Aurelius
UROLOGIE, 2023, : 1295 - 1301
[28] Novel Strategies for Treating Castration-Resistant Prostate Cancer
Leung, David Ka-Wai
Chiu, Peter Ka-Fung
Ng, Chi-Fai
Teoh, Jeremy Yuen-Chun
BIOMEDICINES, 2021, 9 (04)
[29] Novel agents for the management of castration-resistant prostate cancer
Haddad, Housam
Garcia, Jorge A.
CURRENT OPINION IN UROLOGY, 2012, 22 (03) : 175 - 182
[30] Novel hormonal therapy for castration-resistant prostate cancer
Sternberg, C. N.
ANNALS OF ONCOLOGY, 2012, 23 : 259 - 263

← 1 2 3 4 5 →